Annovis Bio

Annovis Bio

Maria Maccecchini founded Annovis Bio in 2008, loading the company's pipeline with a distinctly unified hypothesis: neurodegenerative diseases share common upstream protein pathologies that a single intervention can normalize. Prior to Annovis, Maccecchini built and sold two biotech platforms — Symphony Pharmaceuticals and an earlier venture — and she anchors the company's R&D direction from its headquarters in Malvern, Pennsylvania. The firm operates as a clinical-stage biotechnology company listed on the NYSE American exchange under the ticker ANVS. Annovis concentrates its entire platform on buntanetap, an orally administered small molecule that selectively inhibits the translation of amyloid precursor protein, tau, and alpha-synuclein. The drug does not attack aggregated plaques; it reduces the manufacturing of the toxic proteins that form them. The company is running a phase 3 trial in early Parkinson's disease, with topline data expected in 2024, and it previously reported phase 2/3 data in Alzheimer's disease that showed statistically significant cognitive improvement in a subgroup of early-stage patients. Other pipeline indications include advanced Alzheimer's and neurodegenerative ocular diseases. The geographic footprint is U.S.-centric, with clinical trial sites concentrated across North American academic medical centers. Annovis operates with a lean structure — Maccecchini remains the controlling scientific voice as CEO and the principal inventor on the core patents. The company raised capital through a series of public offerings on the NYSE American and previously traded on the OTC market. In February 2024, the company announced it had fully enrolled its phase 3 Parkinson's study ahead of schedule, an operational milestone that triggered a sharp market reaction. The firm also maintains a research collaboration with the Karolinska Institute in Sweden to study buntanetap's effect on traumatic brain injury biomarkers. Annovis's structural posture is unusual because it has placed an entire company's market value on a single asset with a non-traditional mechanism of action. It is not a diversified platform or a discovery-engine biotech pitching a broad toolbox — it is a binary bet on translational inhibition executed by a founder-CEO scientist who has seen two prior exits. That concentrated governance and scientific strategy differentiate it from the asset-heavy neurodegeneration franchises inside large-cap pharma.